BioWorld

Oct. 19, 2007

MacroGenics, Lilly Ink $1B Deal For Diabetes Drug Teplizumab

MacroGenics Inc. has entered into a deal with Eli Lilly and Co. that could be worth more than $1 billion to develop and commercialize the biotech's lead product teplizumab. (BioWorld Today) Read More

Aspreva Ends Speculation With $915M Acquisition

Studies Examine Relationship Of CF Mutation, Protein Processing

Hard-Pressed Pfizer Dropping Exubera; Nektar Shares Slump

Vertex Slides On Competitor Schering's Positive HCV Data

Earnings Roundup

Other News To Note

Clinic Roundup

Financings Roundup

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 12, 2025

At CROI, HIV cure trials raise hopes for broader applicability

BioWorld

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...

Hummingbird migrates ADCs, tech to newco Callio’s $187M debut

BioWorld

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...